These investment-banking institutions routinely have taken aim at larger, more lucrative deals because bigger companies can afford not to ... B Taylor - 《Oil & Gas Investor》 被引量: 0发表: 2005年 PHARMA? THINK SMALL If you're looking for a growth play in the drug business, small is ...
Palghar pharma firm gets FDA show-cause notice for illegal export of opioids As per an official release of the FDA, the action was taken after a media report highlighted that Tapentadol and Carisoprodol manufactured in India were illegally exported to African countries, where they are misused for...
(TMT) 131 Energy, Mining & Utilities 10.1 124 Industrials & Chemicals 7.9 108 Financial Services 6.9 99 Pharma, Medical 6.4 & Biotech Source: Mergermarket *YTD reflects as of 8/24/2015 Cornell Wright Partner and Co-Head of M&A Practice, Torys LLP James Roddy Josh Benn Head of Mid-Cap ...
参考文献: 1.McConaghie, A. Biopharma’s Winners And Losers Of 2023: Obesity Drugs Reshape Big Pharma. Scrip. 21. 12. 2023. 2.Changurde, A. Pharma’s Voluntary Licensing In India Successful In 2021 – But There Were Some...
2024年3月28日,印度商工部发布公告称,应印度国内企业Piramal Pharma Limited提交的申请,对原产于或进口自中国、欧盟和瑞士的维生素A棕榈酸酯(Vitamin- A Palmitate)启动反倾销调查。涉案产品包括无论是否稳定、所有强度和形式的Vitamin-A Palmitate...
2024年3月28日,印度商工部发布公告称,应印度国内企业Piramal Pharma Limited提交的申请,对原产于或进口自中国、欧盟和瑞士的维生素A棕榈酸酯(Vitamin- A Palmitate)启动反倾销调查。涉案产品包括无论是否稳定、所有强度和形式的Vitamin-A Pa...
除上述企业外, Vedanta Limited,Hetero Pharma Company, Hero MotoCorp, Rashmi Group和DLF Group等公司、集团也曾在遭遇中央机构搜查后购买了选举债券,披着法律外衣将政治腐败合法化的类似事件不胜枚举,针对印人党政府采取不正当手段以公谋私获取政治捐款的质疑也...
https://egazette.nic.in/WriteReadData/2024/253505.pdf 印度对涉华维生素A棕榈酸酯启动反倾销调查 2024年3月28日,印度商工部发布公告称,应印度国内企业Piramal Pharma Limited提交的申请,对原产于或进口自中国、欧盟和瑞士的维生素A棕榈酸酯(Vitamin- A Palmitate)启动反倾...
2023年4月6日,美国West Pharmaceutical Services, Inc. of Exton, Pennsylvania、以色列West Pharma. Services IL, Ltd. of Raꞌanana, Israel向美国ITC提出337立案调查申请,主张对美出口、在美进口和在美销售的该产品侵犯了其知识产权(美国注册专利号10,688,295,美国注册设...
此外,礼来(Eli Lilly and Company)公司开发的GLP-1/GIP受体双重激动剂tirzepatide,和勃林格殷格翰(Boehringer Ingelheim)与Zealand Pharma联合开发的GLP-1/胰高血糖素受体双重激动剂survodutide,今年2月均在治疗NASH的2期临床试验获得初步...